Despite these advances in cancer treatment, only a small subset of cancer patients actually benefits from anti-PD-(L)1 immunotherapy either due to tumor cells not responding to the therapy (primary resistance) or due to tumor cells developing resistance to the therapy (acquired resistance) [1,5,6,7,8,9]. This evidence concerns the gene CD274 and cancer.